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Objective: To assess the feasibility and outcomes of primary percutaneous coronary inter-
vention (PPCI) for ST-segment elevation myocardial infarction (STEMI) in Indian Scenario.
Methods: Between January 2005 and December 2012, consecutive STEMI patients who
underwent PPCI within 12 h of onset of chest pain were prospectively enrolled in a PPCI
registry. Patient demographics, risk factors, procedural characteristics, time variables and
in-hospital and 30 day major adverse cardiovascular events (MACE) [death, reinfarction,
bleeding, urgent coronary artery bypass surgery (CABG) and stroke] were assessed.
Results: A total of 672 patients underwent PPCI during this period. The mean age was
52  13.4 years and 583 (86.7%) were males, 275 (40.9%) were hypertensives and 336 (50%)
were diabetics. Thirty one (4.6%) patients had cardiogenic shock (CS). Anterior myocardial
infarction was diagnosed in 398 (59.2%) patients. The median chest pain onset to hospital
arrival time, door-to-balloon time and total ischemic times were 200 (10e720), 65 (20e300),
and 275 (55e785) minutes respectively. In-hospital adverse events occurred in 54 (8.0%)
patients [death 28 (4.2%), reinfarction 8 (1.2%), major bleeding 9 (1.3%), urgent CABG 4 (0.6%)
and stroke 1 (0.14%)]. Nineteen patients with CS died (mortality rate e (61.3%)). At the end
of 30 days, 64 (9.5%) patients had MACE [death 35 (5.2%), reinfarction 10 (2.1%), major
bleeding 10 (1.5%), urgent CABG 4 (0.6%) and stroke 1 (0.1%)].3; fax: þ91 44 26565859.
(A.S. Mullasari).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 2 5e3 026Conclusion: Our study has shown that PPCI is feasible with good outcomes in Indian scenario.
Even though the recommended door-to-balloon time can be achieved, the total ischemic
time remained long. CS in the setting of STEMI was associated with poor outcomes.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Coronary artery disease (CAD) is the most common non-
infectious disease in India and by 2015, it is estimated to affect
over 65 million of its population. Acute ST-segment elevation
myocardial infarction (STEMI) is the most dramatic manifesta-
tion of CAD with high morbidity and mortality and timely
reperfusion therapy has undoubtedly proved to reduce these
adverse events.1 Primary percutaneous coronary intervention
(PPCI) is themost effective therapy for STEMI andachieves rapid
and more consistent reperfusion with low complication rate
when compared to thrombolysis.2 This prospective, observa-
tional study evaluates the feasibility and outcome of PPCI in
Indian scenario.2. Materials and methods
Between January 2005 and December 2012, consecutive STEMI
patients who underwent percutaneous coronary intervention
(PCI) within 12 h of onset of chest pain were prospectively
enrolled in a PPCI registry. This includes all patients admitted
directly to coronary care unit (CCU) and those transferred
from nearby referral hospitals. Patients with cardiogenic
shock (CS) were also included in the registry. Patients who
underwent rescue PCI were excluded. The protocol was
cleared by institutional ethics committee.
Once a patient was received in the CCU and the diagnosis
of STEMI was confirmed, the in-house catheterization labo-
ratory team was notified. All patients underwent brief history
taking to rule out any contraindication to dual antiplatelet
treatment and a focused clinical examination to assess the
need for mechanical ventilation or circulatory support. A
screening echocardiography was done to exclude any me-
chanical complications. After obtaining informed consent, all
patients were loaded with 325 mg of aspirin, 300e600 mg of
clopidogrel and 40e80 mg of atorvastatin and transferred to
the catheterization laboratory as early as possible.
Procedure was performed either through radial or femoral
route. Elective intra-aortic balloon pump was inserted in pa-
tientswith CS. Non-infarct related artery was imaged first with
a diagnostic catheter to rule out any critical lesions with
compromised blood flow. Then, 70e100 U/kg heparin was
administered intra arterially through the sheath to maintain
the activated clotting time (ACT) between 250 and 300 s. Infarct
related artery (IRA) was engaged with an appropriate sized
guiding catheter and the culprit lesion was crossed with non-
hydrophilic soft 0.01400 guide wire. After lesion crossing, the
TIMI flow and thrombus burden were assessed. If TIMI flow
was grade III and thrombus burdenwas low (TIMI grade 1 or 2),
the lesion was stented directly. Conversely, when there waslarge thrombus burden, aspiration thrombectomy was done
using Export aspiration catheter (Medtronic, Minneapolis,
Minnesota) and balloon dilatation was done if the lesion was
too tight to allow the passage of the stent or when it was
difficult to assess the size of the distal vessel. Intracoronary (IC)
nitroglycerine was administered when the hemodynamics
permitted to excludeany epicardial coronary spasm. ICanti no-
reflow medications and GP IIb-IIIa inhibitors were given ac-
cording to the need. As per the hospital protocol, bare metal
stents (BMS)were used inmost of the patients and drug-eluting
stents (DES) were used when the patient or lesion character-
istics were at high risk for restenosis. In case of multi-vessel
disease, PCI is limited to IRA unless patient had significant
stenosis with less than TIMI III flow in a non-IRA or patientwas
in cardiogenic shock. Time from pain onset to hospital arrival,
door-to-balloon time and total ischemic time were recorded.
Patients were transferred back to CCU post-procedure and
arterial sheath was removed when ACT was less than 150 s.
Hemodynamically stable patients were transferred to the
wards after 24 h and discharged on the third day. At the time of
discharge, all the patientswere continuedondual antiplatelets,
statin, beta-blocker and ACE inhibitor if not contraindicated. In
hospital adverse events (death, reinfarction, urgent CABG,
bleeding and stroke) were noted and they were followed up for
30 days. At 30 days all patients were reviewed clinically in the
out patient department and medications were optimized.
Those who did not come to the OPD were contacted through
telephone. Patient with multi-vessel disease underwent follow
up angiogram between 6 and 8 weeks and had either angio-
plasty or surgery according to the coronary anatomy.3. Definitions
STEMI: Angina or anginal equivalent lasting for >20 min and
ST-segment elevation of 1 mm in 2 contiguous leads, or
new left bundle branch block, or true posterior MI with ST
depression of 1 mm in 2 contiguous anterior leads.
Cardiogenic shock: Sustained hypotension with systolic
blood pressure less than 90 mmHg for at least 30 min, unre-
sponsive to fluid administration and associated with features
of tissue hypoperfusion.
Diabetes mellitus: Fasting glucose > 126 mg/dL or on
treatment.
Systemic hypertension: Systolic blood pressure
>140 mmHg and or Diastolic pressure >90 mmHg, or on
treatment.
Dyslipidemia: Fasting cholesterol >200 mg/dL or on
treatment.
Multivessel disease: Presence of >50% stenosis in 2
epicardial vessels.
Table 1 e Baseline demographic and clinical
characteristics.
Characteristic Number (%)
Age (mean  SD) (years) 52  13.4
Male gender 583 (86.6)
Past medical history
Systemic Hypertension 275 (40.9)
Diabetes 336 (50)
Dyslipidemia 103 (15.3)
Current Smoker 169 (25.1)
Family History of CAD 47 (6.9)
Prior MI 34 (5.1)
Prior PCI 14 (2.1)
Prior CVA 4 (0.6)
Prior Renal Dysfunction 13 (1.9)
Clinical characteristics
Anterior myocardial infarction 398 (59.2)
Cardiogenic Shock 31 (4.6)
Heart rate (mean  SD) (beats/min) 78  18
Blood pressure (mmHg)
Systolic (mean  SD) 127  30
Diastolic (mean  SD) 82  20
Serum Creatinine (mean  SD) (mg/dl) 0.95  0.3
CK total (mean  SD) (IU/L) 2054  2038
Left ventricular ejection fraction (mean)
(%)
41.7  20.8%
Intra aortic balloon pump 40 (6)
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establishment of IRA flow.
Total ischemic time: Time from pain onset to establish-
ment of IRA flow.
Coronary flow: Coronary flow of the infarct related artery
was assessed visually by the operator and classified according
to the TIMI grading system on a scale of 0e3 both before and
after the PCI.
Procedural success: PCI success was defined as achieve-
ment of vessel patency to a residual stenosis <30%.
Re-infarction: Recurrent chest pain or ischemic equivalent
symptoms lasting 30 min and new ECG changes consistent
with reinfarction and the next CK-MB (or CK) level measured
approximately 8e12 h after the event was at least 50% above
the previous level or >3 upper limit of normal, whichever
was greater.
Major bleeding: Occurrence of any of the following: intra-
cranial bleeding, intraocular bleeding, retroperitoneal
bleeding, access site hemorrhage requiring surgery or a
radiological or interventional procedure, hematoma 5 cm in
diameter at the puncture site, reduction in hemoglobin con-
centration of 4 g/dL without an overt source of bleeding,
reduction in hemoglobin concentration of 3 g/dL with an
overt source of bleeding, re-operation for bleeding, or use of
any blood product transfusion.
Mechanical ventilation 26 (5.4)
Temporary pacemaker 52 (7.7)
Hospital stay (mean  SD) (days) 3.4  1.4
Table 2 e Procedural characteristics.
Characteristic Number (%)
Culprit Vessel:
Left anterior descending 378 (56.2)
Left circumflex 70 (10.4)4. Statistical analysis
All the variables were entered into the Statistical Package for
Social Sciences software, version 15 (SPSS Inc) for data anal-
ysis. Continuous variables like age, LVEF were presented as
means and standard deviations and timing variables like
symptom onset to presentation at hospital, door-to-balloon
time and total ischemic time were expressed as median and
range. Categorical variables like gender, risk factors, cardio-
genic shock, left ventricular failure, multi-vessel disease,
procedural success, mortality and 30-day outcomes were all
reported as percentages.Right coronary artery 209 (30.1)
LMCA 10 (1.5)
Multi-vessel CAD 252 (37.5)
Pre-PCI TIMI flow
TIMI 0 409 (60.9)
TIMI I 168 (25)
TIMI II 59 (8.8)
TIMI III 36 (5.4)
Direct stenting 128 (19.0)
PTCA þ stenting 513 (76.3)
Plain old balloon angioplasty (POBA) 31 (4.6)
Multi-vessel PCI 10 (2.1)
Total no. of stents used 712
Bare metal stent 488 (68.5)
Drug eluting stent 224 (31.5)
Thrombosuction 228 (33.9)
GP IIb IIIa inhibitor 389 (57.8)
Post-PCI TIMI flow
TIMI 0 1 (0.1)
TIMI I 32 (4.8)
TIMI II 65 (9.7)
TIMI III 574 (85.4)
Procedural success 639 (95.1)5. Results
Between January 2005 and December 2012, a total of 5691 PCIs
were done at our center, of which 672 (11.8%) were PPCIs.
Table 1 shows the demographic and clinical characteristics of
the cohort. Males were 86.7%, majority had anterior wall MI
(59.2%) and almost half of the patients were diabetics (50%).
Table 2 depicts the angiographic and procedural charac-
teristics. Left anterior descending coronary artery was the
most common culprit vessel accounting for 378 patients
(56.2%), followed by right coronary artery 209 (30.1%) patients.
Multi-vessel disease was present in 252 (37.5%) patients.
Stents were deployed in 641 (95.4%) patients and multivessel
PCI was performed in 10 (2.1%) patients. Procedure was suc-
cessful in 639 (95.1%) patients.
Table 3 summarizes timing intervals to PCI. The median
symptom onset to hospital arrival time was 200 (10e720) min.
The median door-to-balloon time was 65 (20e300) min andless than 90 min in 506 (75.3%) patients. The median total
ischemic time was 275 (55e785) min.
16 (2.5%) patients were lost to follow-up. Table 4 summa-
rizes in-hospital and 30-day outcomes and Table 5
Table 3 e Timing variables.
Time variable Number (%)
Symptom onset to hospital arrival time
[median (range)]
200 (10e720)
120 167 (24.9)
121e240 246 (36.6)
241e360 131 (19.5)
>360 128 (19.0)
Door to balloon time [median (range)] 65 (20e300)
60 309 (46)
60e90 197 (29.3)
91e120 94 (14)
>120 72 (10.8)
Total ischemic time [median (range)] 275 (55e785)
<120 62 (9.2)
121e240 219 (32.6)
241e360 203 (30.2)
>360 188 (28)
Table 4 e 30-day major adverse cardiovascular events
(MACE).
Adverse event Number (%)
In-hospital Follow-up Total
Death 28 (4.2) 7 (1.0) 35 (5.2)
Death (cardiogenic shock) 19 (61.3) 0 (0) 19 (61.3)
Death (No cardiogenic shock) 9 (1.4) 7 (1.1) 16 (2.5)
Re-infarction 8 (1.2) 2 (0.4) 10 (1.6)
Mechanical complications 4 (0.6) 0 (0) 4 (0.6)
CABG 4 (0.6) 0 (0) 4 (0.6)
Major bleeding 9 (1.3) 1 (0.1) 10 (1.4)
Stroke 1 (0.1) 0 1 (0.1)
Total event rate 54 (8.0) 10 (1.5) 64 (9.5)
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(9.5%) patients. The 30-day mortality was 5.2% with 61.3%
mortality in CS. four (0.6%) patients had emergency coronary
artery bypass surgerywhereas 4 (0.6%) had emergency surgery
for mechanical complications. Major TIMI bleeding requiring
transfusion occurred in 10 (1.5%) patients.Table 5 e Medications at 30 days.
Medication Number (%)
Aspirin 616 (99.2)
Clopidogrel 615 (99.0)
Statin 585 (94.2)
Beta-blocker 515 (82.9)
ACE/ARB 532 (85.7)6. Discussion
The main observations of our study are: (1) overwhelming
majority of patients were males (86.3%), (2) diabetes was the
most common risk factor (50%), (3) the median door-to-
balloon time was within international recommendations
(60 min), (4) the median total ischemic time was 275 min, (5)
the overall 30-day mortality was 5.2% and 61.3% in the CS
subset.
Prompt restoration of blood flow in the occluded coronary
artery and rapid establishment of myocardial perfusion form
the basis of STEMI therapy. Even though both thrombolysis
and PPCI have been proven to achieve these goals effectively,
PPCI has outperformed thrombolysis in many respects. First,
thrombolysis restores the IRA patency in fewer (40e60%) pa-
tients in contrast to PPCI (more than 90%). Secondly, throm-
bolysis is less effective when total ischemic time exceeds 6 h
when thrombus maturation occurs. Thirdly, up to 25% of pa-
tients have contraindication to thrombolysis.3 Finally,
improved hard outcomes in terms of death, myocardial
infarction, stroke and bleeding with PPCI makes this the
preferred therapy in the setting of STEMI.2 However, the pro-
portion of patients receiving this treatment remains low in
India.4 In the prospective CREATE registry, which enrolled
patients with acute coronary syndrome in 80 centers in
various parts of the country, PCI was performed in only 8% of
the patients presenting with acute STEMI.5 Even though the
number of centers performing PCI increased since then, there
is no substantial improvement in the proportion of patients
undergoing PPCI.6
Our hospital started 24  7 PPCI program in 2005 with an in
house cardiologist and catheterization laboratory team so
that PCI could be started without delay. Management alsointroduced a financial policy in which the patient would only
pay a token amount as an initial payment (approximately 10%
of the procedure cost) before the PPCI is undertaken and the
remainingmoney can be paid at discharge. Our PCI rates have
improved from 18 cases in 2005 to 191 in 2012. Links were
created with nearby non-PCI hospitals so that eligible patients
after loading with antiplatelets could be transferred without
delay. During transfer, the coronary care unit and catheteri-
zation laboratory are informed prior and after ruling out me-
chanical complications by echocardiography patients are
transferred to the catheterization laboratory.
The mean age of our cohort was 52 years, considerably
younger than patients presenting with STEMI from the west
and similar to STEMI subset of CREATE registry.
86% of our patients were males, slightly more than the
CREATE subset. In contrast to CREATE, diabetes was more
prevalent while smoking and previous history of myocardial
infarction was less prevalent in our patients.5
Time to treatment or total ischemic time is the most
important determinant of not only myocardial salvage but
also mortality.7,8 It starts from the onset of symptoms of
myocardial infarction to the initiation of reperfusion. It en-
compasses two time periods: (1) the time from onset of chest
pain to patient arrival at the hospital and (2) the time from
patient arrival to the initiation of reperfusion therapy,
commonly known as door-to-balloon time.9,10 The impor-
tance of time to treatment has been shown elegantly in ani-
mal studies by Reimer et al.11 Following ligation of left
circumflex coronary artery about 45% of the area under risk
was necrosed within 40 min; it increased to 67% at 3 h and by
6 h only 16% of the myocardium remained viable. This was
later confirmed in human STEMI by usingmagnetic resonance
imaging.12e14 Thus, the amount of salvageable myocardium is
time dependant and gave birth to the concept of “time is
muscle”. The main determinant of total ischemic time is time
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median pain onset to hospital arrival timewas 360min, nearly
twice the current reported time in developed countries. The
various reasons noted for the delay were lack of awareness,
paucity of transport facilities, financial difficulties, and inac-
curate diagnosis.5 With such total ischemic times, when they
undergo reperfusion, most of the myocardium would be
infarcted. Moreover, thrombolysis, the most common reper-
fusion strategy in India, is largely in effective. Even though,
most of our patients come fromnearby areas, themedian pain
onset to hospital arrival was 200 min.
Door-to-balloon time, the second part of time to treatment
is the standard metric used to assess hospitals capability to
manage STEMI with mechanical reperfusion. Both ACC and
ESC propose a door-to-balloon time of 90 min or PCI related
delay of 60 min as standard as beyond which the benefit of
PPCI over fibrinolysis is lost.15,16 We could achieve this in
nearly 75.3% of the patients. 46% of the patients had door-to-
balloon time of less than 60 min. Though we had an in-house
catheterization teamwith an aim to achieve the optimal door-
to-balloon time in all patients, for the most part time was lost
in patient making the decision about the revascularization
strategy.17
The procedural success in our study was 95.1%. The pri-
mary outcomes (death, reinfarction, urgent CABG, major
bleeding and stroke) occurred in 64 (9.5%) patients. The overall
30-day survival was 94.8%. 16 patients out of 641patients
without cardiogenic shock died at 30 days with the mortality
rate of 2.5%,which is similar to outcomes in studies of primary
angioplasty from both developing countries and the west.18,19
31 patients presented to us with CS, of which 19 died with a
mortality rate of 61.3%, which was slightly more than the
mortality in SHOCK study.20 Most of our patients 589 (87.7%)
were discharged within 3days. Follow-up data is available in
97.4% of the patients. Almost all the patients were on dual
anti-platelets and a high number of patients were on statin,
beta-blocker and ACE-inhibitor or ARB.7. Limitations
This is a single center observational study conducted in a
tertiary care hospital with limited applicability to the rest of
the country. Patients were followed up for only 30 days.8. Conclusion
Our study has shown that PPCI is feasible with good outcomes
in Indian scenario. Even though the recommended door-to-
balloon time can be achieved in most of the patients the
total ischemic time remained long. Increased public aware-
ness needed to improve outcomes in acute MI.Conflicts of interest
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Three-dimensional (3D) echocardiography has rapidly
evolved into a useful imaging modality since its advent on the
clinical horizon from the research labs about a decade ago.
From primarily being considered as a modality which only
offered an improved image quality and did not have anymajor
quantitative possibilities, real time 3D echocardiography has
come a long way in a relatively short time span. It has been
shown to be reliable, reproducible and accurate. Volumetric
analysis has been simplified and shown to be comparable to
the current gold standard e cardiac MRI. The objectivity
introduced, ease of use, coupled with excellent reproducibility
has come as a boon for measuring volumes and LV ejection
fraction e one of the most useful prognostic parameter in
cardiology. In valvular heart disease, 3D derived planimetry of
themitral valve is the current echocardiographic gold standard
in mitral stenosis. The repair revolution in mitral valve
regurgitation is driving on due to the views provided by 3D
echocardiography. In the cath lab too, the percutaneous in-
terventions like transcatheter aortic valve implantation, Mitra-
clip, atrial septal defect closure, paravalvular regurgitation
closure are all being facilitated by the unique perspectives
provided by real time 3D transesophageal echocardiography.
Unfortunately, in spite of the obvious advantages offered
by the technique, its use has not spread in the country to the
extent possible. The physicians, accustomed over the years to
viewing the two-dimensional (2D) images, seem intimidated
by the new technique and its nuances. This is partly because
of lack of good quality texts dealing with the subject and its
application in day to day clinical practice. There has thus been
a felt need among the echocardiographers to understand this
new modality. This is evident in the interest generated and
the attendance in the various workshops conducted on 3D
echocardiography.
This book, “Manual of 3D Echocardiography” put together
by Dr V Amuthan and his esteemed colleagues, thus could not
have been more aptly timed. An eminent cardiologist of the
country, Dr Amuthan is an emeritus professor at the Tamil
Nadu MGR Medical University, Chennai. He was formerly the
head of the department at Madurai Medical College in Tamil
Nadu. He is also the Vice President of the Indian academy of
echocardiography. Even at this age, he has tremendous in-
terest in the field of echocardiography, particularly, 3D echo-
cardiography, and is a regular at various conferences and
events in cardiology. It came as no surprise therefore, that hethought of taking up this task of writing a manual of 3D
echocardiography.
The book begins with chapters on the scope of 3D
echocardiography and its various modes. There is a
description of equipment and the unique features of 3D
imaging like slicing and cropping. The book then moves on
to explain the role of 3D echo in various clinical conditions
with chapters on rheumatic heart disease, coronary artery
disease and congenital heart disease with abundant illus-
trations and references on 3D transthoracic and trans-
esophageal echocardiography. There are separate chapters
on 3D TEE guidance in interventions and on device closure
of atrial septal defects, a field where 3D TEE is fast becoming
indispensable. At the end of the book, there is an atlas of 3D
echo images covering some of the common cardiac condi-
tions such as dissection flaps, masses, aortic root abscesses
etc. The book is accompanied by 3 DVDs containing video
recordings of the lectures on 3D echocardiography and
workshops demonstrating the use of 3D echocardiography
in cardiac interventions such as balloon mitral valvotomy.
However, there were just a few points which we found
worth mentioning. The images in the atlas are not labelled,
which makes it somewhat difficult for a beginner to identify
the lesions. In addition, a mention of the mode of 3D echo
used to obtain these images would have been welcome. In the
DVDs, inclusion of 3D clips of various disease states would
have been very useful. This would have added to the infor-
mation needed by the interested readers in understanding the
3D images.
All in all, a good beginning for the texts on 3D echocardi-
ography, in our country!
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